Minocycline foam - Foamix

Drug Profile

Minocycline foam - Foamix

Alternative Names: FMX 101; FMX 102; FMX 103; FXFM-244

Latest Information Update: 08 May 2017

Price : $50

At a glance

  • Originator Foamix
  • Class Amides; Antibacterials; Dimethylamines; Neuroprotectants; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Phase II Impetigo; Rosacea

Most Recent Events

  • 09 May 2017 Foamix announces intention to submit NDA to the US FDA for Acne in the second half of 2018
  • 01 May 2017 Foamix plans two phase III trials for Rosacea in mid-2017 (NCT03142451)
  • 01 May 2017 Efficacy and adverse event data from two phase III trials (Trials 04 and 05) in Acne released by Foamix Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top